Trial Profile
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Status:
Not stated
Phase of Trial:
Phase II/III
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Folinic acid; Hydrocortisone; Methotrexate; Methotrexate; Methylprednisolone; Prednisolone; Prednisone; Vincristine
- Indications B-cell leukaemia; B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms Inter-B-NHL ritux 2010
- 16 Feb 2024 This study has been completed in Poland, according to European Clinical Trials Database record.
- 23 Oct 2023 This study has been completed in Netherland, according to European Clinical Trials Database record.
- 27 Sep 2021 Primary endpoint (Event free survival) has not been met, according to Results published in the Journal of Clinical Oncology.